Long-Term Human Immunodeficiency Virus Infection i Bisexual Men with Normal CD4+ Lymphocyte Counts: I Characteristics

Journal of Infectious Diseases 163, 959-965

DOI: 10.1093/infdis/163.5.959

Citation Report

#	Article	IF	CITATIONS
1	Immunopathogenesis of HIV infection. FASEB Journal, 1991, 5, 2382-2390.	0.5	208
2	Progression and Clinical Outcome of Infection Due to Human Immunodeficiency Virus. Clinical Infectious Diseases, 1992, 14, 966-972.	5.8	36
3	The Natural History and Pathogenesis of HIV Infection. Annual Review of Microbiology, 1992, 46, 533-564.	7.3	36
4	Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 8852-8855.	7.1	58
6	Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet, The, 1992, 340, 863-867.	13.7	234
7	Immunodeficiency. Current Opinion in Immunology, 1992, 4, 523-543.	5.5	O
8	Evaluation of prognosis and survival of the HIV-infected patient. Oral Surgery, Oral Medicine, and Oral Pathology, 1992, 74, 386-392.	0.6	12
9	The transmission of HIV and factors influencing progression to AIDS. American Journal of Medicine, 1993, 95, 86-100.	1.5	61
10	Prognostic Significance of Oral Lesions in Children With Perinatally Acquired Human Immunodeficiency Virus Infection. JAMA Pediatrics, 1993, 147, 45.	3.0	16
11	Normal Immune Function and Inability to Isolate Virus in Culture in an Individual with Long-Term Human Immunodeficiency Virus Type 1 Infection*. AIDS Research and Human Retroviruses, 1994, 10, 395-403.	1.1	73
12	Characteristics of Long-Term Asymptomatic Infection with Human Immunodeficiency Virus Type 1 in Men with Normal and Low CD4+ Cell Counts. Journal of Infectious Diseases, 1994, 169, 1236-1243.	4.0	104
13	Quantitation of human immunodeficiency virus plasma RNA by branched DNA and reverse transcription coupled polymerase chain reaction assay methods: A critical evaluation of accuracy and reproducibility. Serodiagnosis and Immunotherapy in Infectious Disease, 1994, 6, 233-239.	0.2	23
14	HIV-1 reactivation after an oxidative stress mediated by different reactive oxygen species. Chemico-Biological Interactions, 1994, 91, 79-89.	4.0	35
15	Changing Virus-Host Interactions in the Course of HIV-1 Infection. Immunological Reviews, 1994, 140, 35-72.	6.0	161
16	Are human genes risk factors for AIDS?. Nature Genetics, 1994, 7, 456-457.	21.4	3
17	HIV: The surgeon's perspective Part 1. Update of pathogenesis, epidemiology and management and risk of nosocomial transmission. British Journal of Oral and Maxillofacial Surgery, 1994, 32, 222-230.	0.8	5
18	Cd8+ Lymphocyte Activation At Human Immunodeficiency Virus Type 1 Seroconversion: Development Of Hla-Dr+ Cd38- Cd8+ Cells Is Associated With Subsequent Stable Cd4+ Cell Levels. Journal of Infectious Diseases, 1994, 170, 775-781.	4.0	188
19	Direct involvement of extracellular HIV-1 virions in the apoptosis of CD8+ lymphocytes: A two-step model. Medical Hypotheses, 1994, 42, 159-168.	1.5	5

#	ARTICLE	IF	CITATIONS
20	Higher socioeconomic status is associated with slower progression of HIV infection independent of access to health care. Journal of Clinical Epidemiology, 1994, 47, 59-67.	5.0	63
21	Modulation of Cellular Gene Expression by HIV Type 1 Infection as Determined by Subtractive Hybridization Cloning: Downregulation of Thymosin $\hat{l}^2$ <sub>4/sub&gt;<i>in Vitro</i>and<i>in Vivo</i>AlDS Research and Human Retroviruses, 1994, 10, 1525-1529.</sub>	1.1	8
22	Long-term Survivors of HIV Infection. Hospital Practice (1995), 1994, 29, 41-52.	1.0	3
24	Virologic and Immunologic Characterization of Long-Term Survivors of Human Immunodeficiency Virus Type 1 Infection., 1995,, 65-76.		1
25	Characteristics of Persons with Late AIDS Diagnosis in the United States. American Journal of Preventive Medicine, 1995, 11, 114-119.	3.0	29
26	Virologic and Immunologic Characterization of Long-Term Survivors of Human Immunodeficiency Virus Type 1 Infection. New England Journal of Medicine, 1995, 332, 201-208.	27.0	1,065
27	Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1995, 332, 209-216.	27.0	717
28	Predictors for Non- and Slow Progression in Human Immunodeficiency Virus (HIV) Type 1 Infection: Low Viral RNA Copy Numbers in Serum and Maintenance of High HIV-1 p24-Specific but Not V3-Specific Antibody Levels. Journal of Infectious Diseases, 1995, 171, 811-821.	4.0	158
29	CD8+ T Lymphocytes and Cytomegalovirus Retinitis in Patients With the Acquired Immunodeficiency Syndrome. American Journal of Ophthalmology, 1995, 120, 283-290.	3.3	26
30	The solution to the seven mysteries of AIDS; The â€~Trojan Horse'. Medical Hypotheses, 1995, 44, 1-9.	1.5	6
31	Long-term survivors of HIV-1 infection. Trends in Microbiology, 1995, 3, 386-391.	7.7	61
32	Is the Nef protein of HIV-1 required for pathogenesis?. Trends in Microbiology, 1996, 4, 171-172.	7.7	3
33	Antiviral immunity in HIV-1 infected long-term non-progressors (LTNPs). Seminars in Virology, 1996, 7, 131-138.	3.9	6
34	Synthetic Peptides Coupled to the Lipotripeptide P3CSS Induce in vivo B and Thelper Cell Responses to HIV-1 Reverse Transcriptase. Immunobiology, 1996, 195, 61-76.	1.9	17
35	The lack of association of Marijuana and other recreational drugs with progression to AIDS in the San Francisco men's health study. Annals of Epidemiology, 1996, 6, 283-289.	1.9	36
36	Comorbidity and survival in HIV-Infected men in the San Francisco Men's Health Survey. Annals of Epidemiology, 1996, 6, 420-430.	1.9	153
37	Toward an Understanding of the Correlates of Protective Immunity to HIV Infection. Science, 1996, 271, 324-328.	12.6	427
38	THE HUMAN IMMUNODEFICIENCY VIRUS. Medical Clinics of North America, 1996, 80, 1239-1261.	2.5	11

#	Article	IF	CITATIONS
40	Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection. Clinical Microbiology Reviews, $1996$ , $9$ , $135-147$ .	13.6	31
41	Immunopathogenic Mechanisms of HIV Infection. Annals of Internal Medicine, 1996, 124, 654.	3.9	395
42	Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS. Immunology Letters, 1996, 51, 23-28.	2.5	21
44	T cell receptor usage and fine specificity of human immunodeficiency virus 1-specific cytotoxic T lymphocyte clones: analysis of quasispecies recognition reveals a dominant response directed against a minor in vivo variant Journal of Experimental Medicine, 1996, 183, 1669-1679.	8.5	62
45	Biological Phenotype of HIV Type 2 Isolates Correlates with V3 Genotype. AIDS Research and Human Retroviruses, 1996, 12, 821-828.	1.1	45
46	Analysis of Human Immunodeficiency Virus Type 1 mRNA Splicing Patterns during Disease Progression in Peripheral Blood Mononuclear Cells from Infected Individuals. AIDS Research and Human Retroviruses, 1996, 12, 1443-1456.	1.1	31
47	IMMUNOPATHOGENESIS OF HIV INFECTION. Annual Review of Microbiology, 1996, 50, 825-854.	7.3	224
48	Primary infection by type 1 human immunodeficiency virus: diagnosis and prognosis. Postgraduate Medical Journal, 1997, 73, 403-408.	1.8	7
49	Augmented Serum Neutralizing Activity against Primary Human Immunodeficiency Virus Type 1 (HIVâ€1) Isolates in Two Groups of HIVâ€1â€Infected Longâ€Term Nonprogressors. Journal of Infectious Diseases, 1997, 176, 1180-1187.	4.0	74
50	Gross Defects in thevprandvpuGenes of HIV Type 1 Cannot Explain the Differences in RNA Copy Number between Long-Term Asymptomatics and Progressors. AIDS Research and Human Retroviruses, 1997, 13, 247-252.	1.1	15
51	Characterization of a Polyclonal Cytolytic T Lymphocyte Response to Human Immunodeficiency Virus in Persons without Clinical Progression. Journal of Infectious Diseases, 1997, 175, 1360-1367.	4.0	23
52	The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 254-258.	7.1	260
53	The viral envelope in the evolution of HIV: a hypothetical approach to inducing an effective immune response to the virus. Medical Hypotheses, 1997, 48, 517-521.	1.5	6
54	Host factors in the pathogenesis of HIV disease. Immunological Reviews, 1997, 159, 31-48.	6.0	187
55	Cardiovascular involvement in AIDS. Current Problems in Cardiology, 1997, 22, 109-148.	2.4	18
56	Genetic Characterization ofvif, vpr,andvpuSequences from Long-Term Survivors of Human Immunodeficiency Virus Type 1 Infection. Virology, 1997, 228, 340-349.	2.4	73
57	Activity of Human Immunodeficiency Virus Type 1 Promoter/TAR Regions and at 1 Genes Derived from Individuals with Different Rates of Disease Progression. Virology, 1997, 232, 319-331.	2.4	35
58	Genetic polymorphism of CCR5 gene and HIV disease: The heterozygous (CCR5/l°*ccr5) genotype is neither essential nor sufficient for protection against disease progression. European Journal of Immunology, 1997, 27, 3223-3227.	2.9	39

#	ARTICLE	IF	CITATIONS
59	Viral Burden and Disease Progression in HIV-1–Infected Patients with Sickle Cell Anemia. American Journal of Hematology, 1998, 59, 199-207.	4.1	35
60	Uncertainty in illness across the HIV/AIDS trajectory. Journal of the Association of Nurses in AIDS Care, 1998, 9, 66-77.	1.0	77
61	Host factors that affect sexual transmission of HIV. International Journal of Infectious Diseases, 1998, 2, 182-185.	3.3	8
62	Correlation between Humoral Responses to Human Immunodeficiency Virus Type 1 Envelope and Disease Progression in Earlyâ€Stage Infection. Journal of Infectious Diseases, 1998, 178, 1306-1316.	4.0	51
63	Presence of HLA-C-Restricted Cytotoxic T-Lymphocyte Responses in Long-Term Nonprogressors Infected with Human Immunodeficiency Virus. Viral Immunology, 1998, 11, 119-129.	1.3	26
64	Predictors of Progression in Long-Term Nonprogressors. AIDS Research and Human Retroviruses, 1998, 14, 117-121.	1.1	29
65	Diminished Spontaneous Apoptosis in Lymphocytes from Human Immunodeficiency Virusâ€Infected Longâ€Term Nonprogressors. Journal of Infectious Diseases, 1998, 178, 669-679.	4.0	55
66	The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis. Aids, 1998, 12, 1537-1544.	2.2	36
67	Rare mutations in a domain crucial for V3-loopstructure prevail in replicating HIV from long-term non-progressors. Aids, 1998, 12, 985-997.	2.2	27
68	Analysis of a Large Collection of Natural HIV-1 Integrase Sequences, Including Those From Long-Term Nonprogressors. Journal of Acquired Immune Deficiency Syndromes, 1998, 19, 99-110.	0.3	16
69	Influence of host genes on HIVâ€1 disease progression. FASEB Journal, 1998, 12, 625-632.	0.5	72
70	A Longitudinal Study of Neutralizing Antibodies and Disease Progression in HIVâ€1–Infected Subjects. Journal of Infectious Diseases, 1999, 179, 1365-1374.	4.0	92
71	Antibody-Dependent Cellular Cytotoxicity in HIV Type 1-Infected Patients Receiving VaxSyn, a Recombinant gp160 Envelope Vaccine. AIDS Research and Human Retroviruses, 1999, 15, 847-854.	1.1	9
72	HIV-infected long-term nonprogressors: epidemiology, mechanisms of delayed progression, and clinical and research implications. Microbes and Infection, 1999, 1, 1113-1120.	1.9	43
73	The Sydney Blood Bank Cohort. Annals of Epidemiology, 1999, 9, 436-440.	1.9	4
74	Placebos, Drug Effects, and Study Design: A Clinician's Guide. American Journal of Psychiatry, 1999, 156, 829-836.	7.2	141
75	Essential medical facts for mental health practitioners. New Directions for Mental Health Services, 2000, 2000, 3-15.	0.4	3
76	Characterization of Human Immunodeficiency Virus Type 1 vif Gene in Long-Term Asymptomatic Individuals. Virology, 2000, 276, 169-180.	2.4	38

#	Article	IF	CITATIONS
77	A Dual Infection/Competition Assay Shows a Correlation between Ex Vivo Human Immunodeficiency Virus Type 1 Fitness and Disease Progression. Journal of Virology, 2000, 74, 9222-9233.	3.4	224
78	Acute Sexually Transmitted Infections Increase Human Immunodeficiency Virus Type 1 Plasma Viremia, Increase Plasma Type 2 Cytokines, and Decrease CD4 Cell Counts. Journal of Infectious Diseases, 2000, 182, 459-466.	4.0	81
79	Progressive Infection in a Subset of HIV‶–Positive Chimpanzees. Journal of Infectious Diseases, 2000, 182, 1051-1062.	4.0	74
80	Immunopathogenesis of HIV-1 infection. Clinics in Dermatology, 2000, 18, 401-410.	1.6	4
81	HIV Type 1-Specific IgG2 Antibodies: Markers of Helper T Cell Type 1 Response and Prognostic Marker of Long-Term Nonprogression. AIDS Research and Human Retroviruses, 2001, 17, 1435-1446.	1.1	81
82	Host Determinants in HIV Infection and Disease: Part 1: Cellular and Humoral Immune Responses*. Annals of Internal Medicine, 2001, 134, 761.	3.9	79
83	Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection. Journal of Medical Primatology, 2001, 30, 207-214.	0.6	39
84	Modelling the Natural History of HIV Infection in Individuals and its Epidemiological Implications. Bulletin of Mathematical Biology, 2001, 63, 1041-1062.	1.9	20
85	High viral burden in the presence of major HIV-specific CD8+ T cell expansions: evidence for impaired CTL effector function. European Journal of Immunology, 2001, 31, 677-686.	2.9	171
86	Introduction: The Etiology of AIDS. , 2002, , 1-10.		0
87	A New Mathematical Model for Assessing Therapeutic Strategies for HIV Infection. Journal of Theoretical Medicine, 2002, 4, 147-155.	0.5	15
88	The CD28/HLA-DR expressions on CD4 + T but not CD8 + T cells are significant predictors for progression to AIDS. Clinical and Experimental Immunology, 2002, 127, 137-144.	2.6	18
89	Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: Associations with viral replication and progression. Journal of Medical Virology, 2003, 71, 483-491.	5.0	18
90	Longitudinal Study of Humoral Immune Responses in HIV Type 1 Subtype CRF01_AE (E)-Infected Thai Patients with Different Rates of Disease Progression. AIDS Research and Human Retroviruses, 2003, 19, 293-305.	1.1	20
91	Natural History and Pathogenesis of Human Immunodeficiency Virus Infection. Seminars in Liver Disease, 2003, 23, 115-124.	3.6	7
92	The Density of Coreceptors at the Surface of CD4+T Cells Contributes to the Extent of Human Immunodeficiency Virus Type $1$ Viral Replication-Mediated T Cell Death. AIDS Research and Human Retroviruses, 2004, 20, 1230-1243.	1.1	15
93	HIV Type 1-Specific Inter- and Intrasubtype Cellular Immune Responses in HIV Type 1-Infected Ugandans. AIDS Research and Human Retroviruses, 2004, 20, 763-771.	1.1	8
94	Can We Really Identify HIV-1 Long-Term Nonprogressors?. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1218-1219.	2.1	4

#	Article	IF	CITATIONS
95	Conserved Neutralizing Epitopes of HIV Type 1 CRF01_AE against Primary Isolates in Long-Term Nonprogressors. AIDS Research and Human Retroviruses, 2004, 20, 531-542.	1.1	13
96	A Randomized Placebo-Controlled Trial of the Impact of Multiple Micronutrient Supplementation on HIV-1 Genital Shedding Among Thai Subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1216-1218.	2.1	4
97	Population-Based Study Evaluating Association Between Selected Antiretroviral Therapies and Potential Oral Contraceptive Failure. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1219-1220.	2.1	7
99	A subset of human immunodeficiency virus type $1$ long-term non-progressors is characterized by the unique presence of ancestral sequences in the viral population. Journal of General Virology, 2005, 86, 355-364.	2.9	27
100	Persistent Anti-Gag, -Nef, and -Rev IgM Levels as Markers of the Impaired Functions of CD4+ T-Helper Lymphocytes During SIVmac251 Infection of Cynomolgus Macaques. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 1-11.	2.1	5
101	Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX® B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine, 2005, 23, 2522-2529.	3.8	93
102	Stromal cell-derived factor 1 (SDF1) genetic polymorphism in a sample of healthy individuals, seronegative individuals exposed to human immunodeficiency virus type 1 (HIV-1) and patients infected with HIV-1 from the Brazilian population. International Journal of Immunogenetics, 2006, 33, 127-133.	1.8	17
103	B cell responses to HIV and the development of human monoclonal antibodies. Clinical and Experimental Immunology, 2008, 88, 189-202.	2.6	15
104	HIV immunopathogenesis and strategies for intervention. Lancet Infectious Diseases, The, 2008, 8, 675-684.	9.1	37
105	Laboratory characteristics of HIV-1 clade C-infected long-term non-progressors at a tertiary human immunodeficiency virus care centre in South India. Journal of Medical Microbiology, 2008, 57, 913-915.	1.8	3
106	Chapter 9 HIV Induced AIDS and Related Cancers. Advances in Cancer Research, 2008, 101, 349-395.	5.0	14
107	HLA Homology within the C5 Domain Promotes Peptide Binding by HIV Type 1 gp120. AIDS Research and Human Retroviruses, 2008, 24, 845-855.	1.1	11
108	Epidemiological, immunological and virological characteristics, and disease progression of HIV-1/HCV-co-infectedc patients from a southern Brazilian population. International Journal of Molecular Medicine, $0, , .$	4.0	6
109	A combination of defective DNA and protective host factors are found in a set of HIV-1 ancestral LTNPs. Virology, 2009, 391, 73-82.	2.4	31
110	Immune activation and antibody responses in nonâ $\in$ progressing elite controller individuals infected with HIVâ $\in$ 1. Journal of Medical Virology, 2009, 81, 1681-1690.	5.0	33
111	HIV Envelope-Specific Antibody and Vaccine Efficacy., 0, , .		1
112	Unravelling the mechanisms of durable control of HIV-1. Nature Reviews Immunology, 2013, 13, 487-498.	22.7	211
113	Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease. Frontiers in Immunology, 2013, 4, 95.	4.8	45

#	Article	IF	Citations
114	Rapid Disease Progression in HIV-1 Subtype C–Infected South African Women. Clinical Infectious Diseases, 2014, 59, 1322-1331.	5.8	46
115	HIV Cure: The Target Is Clearer but Not Yet Close. Annals of Internal Medicine, 2014, 160, 505.	3.9	4
116	Clinical, Virologic and Immunological Outcomes in a Cohort of Long-Term Non-Progressor HIV Infected Patients, Southern Brazil. Journal of AIDS & Clinical Research, 2015, 06, .	0.5	0
117	Discovery of another anti-HIV protein in the search for the CD8+ cell anti-HIV Factor. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7888-7889.	7.1	6
118	Correlation of Antibody Responses to a Peptide Antigen gp120-C5501–512/gp41732–744with HIV Disease Progression. AIDS Research and Human Retroviruses, 2017, 33, 558-566.	1.1	3
119	HIV long-term non-progressors elite controllers: an interplay between host, immune and viral factors. Future Virology, 2019, 14, 287-297.	1.8	4
120	Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control. Journal of Virology, 2019, 93, .	3.4	41
121	Retroviruses—Human Immunodeficiency Virus. , 1997, , 713-783.		10
122	The Human Immunodeficiency Viruses. , 1995, , 1-96.		2
123	Epidemiology and Prevention of Acquired Immunodeficiency Syndrome and Human Immunodeficiency Virus Infection., 2010,, 1635-1661.		1
124	Sexual Behavior and Injection Drug Use During Pregnancy and Vertical Transmission of HIV-1. Journal of Acquired Immune Deficiency Syndromes, 1997, 15, 76-82.	0.3	93
125	Comparative Rates of Disease Progression Among Persons Infected With the Same or Different HIV-1 Strains. Journal of Acquired Immune Deficiency Syndromes, 1997, 15, 145-150.	0.3	22
126	Characterization of Proviral DNA From an Individual With Long-Term, Nonprogressive Infection With HIV-1 and Nonrecoverable Virus. Journal of Acquired Immune Deficiency Syndromes, 1997, 15, 247-256.	0.3	6
127	The rate of progression to AIDS is independent of virus dose in simian immunodeficiency virus-infected macaques. Microbiology (United Kingdom), 2000, 81, 1719-1726.	1.8	13
128	Low Relative Frequencies of CD26 <sup>+</sup> CD4 <sup>+</sup> Cells in Long-Term Nonprogressing Human Immunodeficiency Virus Type 1-Infected Subjects. Vaccine Journal, 1998, 5, 662-666.	2.6	4
129	Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. Journal of Virology, 1994, 68, 6672-6683.	3.4	315
130	Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. Journal of Virology, 1994, 68, 7433-7447.	3.4	328
131	Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. Journal of Virology, 1995, 69, 93-100.	3.4	166

#	Article	IF	CITATIONS
132	Induction of accelerated feline immunodeficiency virus disease by acute-phase virus passage. Journal of Virology, 1995, 69, 6149-6157.	3.4	86
133	Functional characterization of human immunodeficiency virus type 1 nef genes in patients with divergent rates of disease progression. Journal of Virology, 1995, 69, 6758-6769.	3.4	67
134	Biological characterization of nef in long-term survivors of human immunodeficiency virus type 1 infection. Journal of Virology, 1995, 69, 8142-8146.	3.4	59
135	Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. Journal of Virology, 1995, 69, 4228-4236.	3.4	116
136	High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. Journal of Virology, 1995, 69, 5838-5842.	3.4	508
137	High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. Journal of Virology, 1996, 70, 7752-7764.	3.4	208
138	Genotypic and phenotypic characterization of long terminal repeat sequences from long-term survivors of human immunodeficiency virus type 1 infection. Journal of Virology, 1997, 71, 5608-5613.	3.4	41
139	Grossly Defective (i>nef (i) Gene Sequences in a Human Immunodeficiency Virus Type 1-Seropositive Long-Term Nonprogressor. Journal of Virology, 1998, 72, 3646-3657.	3.4	171
140	Association between Virus-Specific Cytotoxic T-Lymphocyte and Helper Responses in Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 1999, 73, 6715-6720.	3.4	329
141	Pathogenesis of human immunodeficiency virus infection. Microbiological Reviews, 1993, 57, 183-289.	10.1	893
142	Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors Journal of Clinical Investigation, 1997, 100, 1581-1589.	8.2	48
143	Socio-demographic and epidemiological characteristics associated with human immunodeficiency virus type I (HIV-1) infection in HIV-1-explosed but uninfected individuals, and in HIV-1-infected patients from a southern brasilian population. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2005, 47, 239-246.	1.1	7
144	Targeting Strategies for Human Immunodeficiency Virus: A Combinatorial Approach. Mini-Reviews in Medicinal Chemistry, 2012, 12, 236-254.	2.4	8
145	Long-Term Non-Progressive HIV Infection. , 2000, , 65-75.		0
146	Overview of the HIV/AIDS Epidemic., 2001,, 13-32.		0
147	Correlations between Apoptosis and HIV Disease Progression. , 2005, , 355-379.		0
148	AIDS: The Uses and Limitations of Science. , 1992, , 31-48.		0
149	The Role of Human Immunodeficiency Virus Type 1 (HIV-1) in Neurologic Disorders of AIDS. , 1992, , 527-589.		3

#	Article	IF	CITATIONS
150	Photoactivation of the Human Immunodeficiency Virus Type 1 Involves Complex Signaling Pathways. , 1994, , 143-160.		0
151	Redox Regulation of the Human Immunodeficiency Virus Type 1 (HIV-1)., 1996,, 249-268.		O
152	Lung Immunology and HIV., 1997,, 15-40.		0
154	Epidemiology and Prevention of Acquired Immunodeficiency Syndrome and Human Immunodeficiency Virus Infection., 2015,, 1483-1502.e8.		5
170	Use of blood donation history of people with HIV infection to identify recipients at risk. Cmaj, 1994, 151, 1147-51.	2.0	0
171	An Observational Study of Genetic Diversity of HIV-1 vpu in Rapid Progressors in India. Current HIV Research, 2023, 21, .	0.5	0